Fidia Farmaceutici is strengthening its position in the fields of urology and cardiology
The Group has completed the acquisition of a portfolio of nine So.Se. Pharm products – more than €300 million has been invested over the last five years
Key points
A new acquisition for Fidia Farmaceutici of Abano Terme, a world leader in the research, development, manufacture and marketing of innovative products, particularly those based on hyaluronic acid and its derivatives. This time, the aim is to acquire pharmaceutical products from So.Se. Pharm srl, the Italian leader in the manufacture and distribution of branded generic medicines, medical devices and dietary supplements, based in Pomezia (Rome) with a production plant in Agnani.
The operation
In this way, Fidia – which is celebrating its 80th anniversary – is expanding its portfolio in the fields of cardiology and urology with the brands Alamut, Antunes, Berny, Crotonil, Dicolev, Ferrogyn, Giachela, Nebiscon and Tadap, which are distributed and sold in Italia and in certain non-EU countries.
This is the eighth financial transaction completed in the last five years, confirming the Group’s ongoing growth trajectory. The backdrop to this is a growth strategy focused on external expansion, which has seen the Group invest more than 300 million euros in acquisitions over the last five years, leading to an increase in Fidia’s turnover and EBITDA of 45 per cent, from €371.2 million to €538.3 million, and by 45.8 per cent, from €75.5 million to €110 million, over the same period.
The Group’s strategy of external growth in recent years coincides with the start of direct management by Carlo Pizzocaro, who has been at the helm of the company since 2016. Founded in 1946, Fidia Farmaceutici is an Italian company and a world leader in the research, development, manufacture and marketing of innovative products based on hyaluronic acid and its derivatives (over 1,250 patents) in the strategic areas of joint care, skin care, eye care, specialty care and health & wellness care. Fidia has a production plant and Research and Development laboratories in Abano Terme (PD), where the company is headquartered, a specialised Research Unit in Noto, and offices in Lombardy and the Marche region. The company distributes its products in over 120 countries.
The strategy
Over the last decade, Fidia has focused its development strategy on transactions aimed at expanding, integrating and diversifying the company’s portfolio. This plan began in 2016 with the acquisition of Biofarmitalia S.r.l., a company active in the development of transdermal patches for the treatment of osteoarticular pain, followed by the acquisition of Sooft Italia spa, a leading Italian company in the ophthalmic sector. Since then, the company has continued to invest in complementary fields, including regenerative medicine, through the incorporation into the Group of Soluciones Bioregenerativas SL, a Spanish company specialising in the production of PRP (Platelet-Rich Plasma).
